Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions

[1]  B. Chauffert,et al.  Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[2]  A. Yoon,et al.  Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[3]  A. Yoon,et al.  A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth , 2015, Oncotarget.

[4]  Peter R. Cook,et al.  Why the activity of a gene depends on its neighbors. , 2015, Trends in genetics : TIG.

[5]  J. Trojan,et al.  Novel drugs in clinical development for hepatocellular carcinoma , 2015, Expert opinion on investigational drugs.

[6]  Zhaohui Tang,et al.  Peritumoral Neuropilin-1 and VEGF receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy , 2014, Oncotarget.

[7]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Rofstad,et al.  Tumor Interstitial Fluid Pressure—A Link between Tumor Hypoxia, Microvascular Density, and Lymph Node Metastasis , 2014, Neoplasia.

[9]  O. Podhajcer,et al.  Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Guan-Cheng Li,et al.  Tumor markers for hepatocellular carcinoma , 2013, Molecular and clinical oncology.

[11]  G. Semenza.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. , 2012, Trends in pharmacological sciences.

[12]  C. Yun,et al.  A Hypoxia- and α-Fetoprotein–Dependent Oncolytic Adenovirus Exhibits Specific Killing of Hepatocellular Carcinomas , 2010, Clinical Cancer Research.

[13]  Hui Zhou,et al.  Liver‐enriched transcription factors regulate MicroRNA‐122 that targets CUTL1 during liver development , 2010, Hepatology.

[14]  Q. Lan,et al.  Development of clinically relevant orthotopic xenograft mouse model of metastatic lung cancer and glioblastoma through surgical tumor tissues injection with trocar , 2010, Journal of experimental & clinical cancer research : CR.

[15]  F. Lang,et al.  Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. , 2009, Current gene therapy.

[16]  O. Podhajcer,et al.  Suppression of cancer growth by nonviral gene therapy based on a novel reactive oxygen species-responsive promoter. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  W. De,et al.  Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer , 2009, Cancer biology & therapy.

[18]  E. Galanis,et al.  Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. , 2009, Methods in molecular biology.

[19]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[20]  H. Yasuda,et al.  Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. , 2008, Nitric oxide : biology and chemistry.

[21]  M. Miyazaki,et al.  Clinical significance of α‐fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma , 2008, Journal of gastroenterology and hepatology.

[22]  P. Stewart,et al.  Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo , 2008, Proceedings of the National Academy of Sciences.

[23]  C. Napoli,et al.  Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer , 2008, Cell.

[24]  R. Johnson,et al.  Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.

[25]  R. Millikan,et al.  CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance , 2006, Clinical Cancer Research.

[26]  A. Parker,et al.  Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. , 2006, Blood.

[27]  Byeong‐Woo Park,et al.  Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. , 2006, Human gene therapy.

[28]  D. Brizel,et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  B. Shen,et al.  Effect of hypoxia on Ad5 infection, transgene expression and replication , 2005, Gene Therapy.

[30]  Bart Everts,et al.  Replication-selective oncolytic viruses in the treatment of cancer , 2005, Cancer Gene Therapy.

[31]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[32]  W. Rom,et al.  278. Hypoxia Reduces Adenoviral Replication in Cancer Cells by Down-Regulation of Viral Protein Expression , 2004 .

[33]  G. Powis,et al.  Hypoxia inducible factor-1alpha as a cancer drug target. , 2004, Molecular cancer therapeutics.

[34]  G. Powis,et al.  Hypoxia inducible factor as a cancer drug target. , 2003, Current cancer drug targets.

[35]  Hoguen Kim,et al.  Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. , 2003, Human gene therapy.

[36]  Erwin G. Van Meir,et al.  Replicative oncolytic adenoviruses in multimodal cancer regimens. , 2003, Human gene therapy.

[37]  K. Jungermann,et al.  Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. , 2003, Blood.

[38]  Joo‐Hang Kim,et al.  Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy , 2002, Cancer Gene Therapy.

[39]  D. Nettelbeck,et al.  Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. , 2002, Cancer research.

[40]  Joo‐Hang Kim,et al.  Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. , 2002, Cancer letters.

[41]  C. Gomer,et al.  Enhanced photodynamic therapy efficacy with inducible suicide gene therapy controlled by the grp promoter. , 2002, Cancer research.

[42]  D. Kirn.  Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials , 2001, Expert opinion on biological therapy.

[43]  M. Colombo.  Screening for cancer in viral hepatitis. , 2001, Clinics in liver disease.

[44]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[46]  M. Gulley,et al.  Erratum: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (Clinical Cancer Research (2000) 6 (798-806)) , 2000 .

[47]  M. Makuuchi,et al.  Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. , 2000, Blood.

[48]  Xianglin Shi,et al.  Regulation of a Cell Type-specific Silencer in the Human Interleukin-3 Gene Promoter by the Transcription Factor YY1 and an AP2 Sequence-recognizing Factor* , 1999, The Journal of Biological Chemistry.

[49]  Y. Chiang,et al.  A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. , 1999, Human gene therapy.

[50]  N. Koide,et al.  α-Fetoprotein–producing gastric cancer: histochemical analysis of cell proliferation, apoptosis, and angiogenesis , 1999, American Journal of Gastroenterology.

[51]  S. Kaneko,et al.  Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. , 1998, Biochemical and biophysical research communications.

[52]  J. Simons,et al.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.

[53]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[54]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[55]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[56]  H. Nakabayashi,et al.  A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma , 1991, Molecular and cellular biology.

[57]  D. W. Kim,et al.  Use of the human elongation factor 1α promoter as a versatile and efficient expression system , 1990 .

[58]  S. Sugano,et al.  Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. , 1990, Gene.

[59]  R. Cortese,et al.  The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain , 1989, Cell.

[60]  K. Watanabe,et al.  Transcriptional regulation of alpha-fetoprotein expression by dexamethasone in human hepatoma cells. , 1989, The Journal of biological chemistry.

[61]  T. Tamaoki,et al.  Interaction of a hepatoma-specific nuclear factor with transcription-regulatory sequences of the human alpha-fetoprotein and albumin genes , 1988, Molecular and cellular biology.

[62]  K. Watanabe,et al.  Cell-specific enhancer activity in a far upstream region of the human alpha-fetoprotein gene. , 1987, The Journal of biological chemistry.

[63]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.